SPOTLIGHT: Novartis asthma drug gets OK from NICE

The UK's National Institute for Clinical Excellence has opened the gate for Novartis' Xolair to be used as an add-on treatment for severe allergic asthma in adults and adolescents. Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.